Life Sciences
Cancer Immunotherapy Expansion using a New Predictive Biomarker
In this Inside Precision Medicine webinar, our distinguished guest speaker, Dr. Scott Tomlins, will describe the development, validation, and clinical…
Broadcast Date: April 6, 2023
Time: 11:00 am PT, 2:00 pm ET, 20:00 CET
Immune checkpoint inhibition with monoclonal antibodies targeting PD-1 and PD-L1 has revolutionized the care of patients with advanced cancer, with approvals in multiple solid tumor types and pan-tumor indications. However, current pan-tumor biomarkers do not identify most patients who benefit from these therapies. For example, consider the KEYNOTE-158 study of 10 tumor types that led to pan-solid tumor approval of second-line pembrolizumab monotherapy in patients whose tumor mutation burden was high (TMB-H). While a higher objective response rate (ORR) was observed in TMB-H patients vs. TMB-low (TMB-L), numerically, more objective responses were observed in TMB-L patients.
In this Inside Precision Medicine Webinar, our distinguished guest speaker, Dr. Scott Tomlins, will describe the development, validation, and clinical utility of a new pan-tumor predictive biomarker for immunotherapy benefit: Immunotherapy Response Score (IRS). IRS predicts real-world progression-free survival and overall survival in anti-PD-1/PD-L1 monotherapy-treated patients across tumor types and identifies twice as many patients who may benefit from checkpoint inhibitor treatment as TMB.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from:
The post Cancer Immunotherapy Expansion using a New Predictive Biomarker appeared first on Inside Precision Medicine.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….